 |
 |
E-MOVE reports from the 61st Annual Meeting of the American Academy of Neurology, held in Seattle, WA, April 25th - May 2nd, 2009. Poster and Session numbers refer to their listing in Neurology, 2009;72(suppl3) Rotigotine transdermal patch was recalled in 2008 due to formation of crystals within the patch. The manufacturers now report the cause of the crystallization is "a previously undiscovered polymorph of rotigotine with an altered three dimensional conformation and subsequently a different packing arrangement of rotigotine molecules." The polymorph forms over time at room temperature, but does not develop significantly at colder temperatures. The manufacturer has taken steps to store and distribute the product under cold conditions. Patients still receiving the medication under special arrangement have been told that no special container is required to transport it home from the pharmacy, and that it needn't be stored in the freezer. Additional work is being done to minimize crystallization. "UCB is committed to returning NeuproŽ to the market," and is working with regulatory agencies in the US and elsewhere to accomplish this. There was no indication of when that return is expected. Supported by UCB Pharma Rotigotine transdermal system: An update JA Zackheim, L Hakes, C Arth, L Bauer, L Dewulf P01.145 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn